4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150. The company will only have to conduct a ...
Researchers have achieved remarkable progress in the field of electromagnetic metamaterials (EMMs) through 3D and 4D printing technologies. This innovation is set to revolutionize multiple industries ...